SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Injective taken over by the community.

Nonja

NONJA CRYPTO is experiencing heightened interest as its passionate community rallies around the Injective ($INJ) ecosystem's growth, driven by recent network developments like the EVM mainnet launch and anticipated INJ ETFs. Many perceive $NONJA as a high-leverage opportunity on Injective's trajectory, emphasizing its strong community and robust liquidity as key factors for significant future gains.

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma Inc

Sutro Biopharma is trending due to its recent reverse stock split, which helped it regain Nasdaq listing compliance, alongside a major corporate restructuring and workforce reduction. The community is actively debating the deprioritization of its lead asset, Luvelta, and the company's strategic pivot towards its next-generation ADC programs. Many investors are keenly focused on the potential for new partnerships for Luvelta and upcoming pipeline milestones, given the company's substantial cash reserves within the competitive biotech sector.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is gaining significant attention, propelled by its AI-powered Athena platform and recent Marigold acquisition. The community is highly optimistic, discussing its perceived undervaluation and anticipating a substantial rerating as GAAP profitability nears and its leadership in AI-driven MarTech with first-party data is increasingly recognized. This positions Zeta as a key player in the evolving digital advertising landscape.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is experiencing a parabolic surge, primarily driven by imminent Chinese export restrictions on silver and a notable increase in industrial demand for green technology, microchips, and AI data centers. The community is fiercely debating whether this represents a historic re-pricing following decades of suppression and dwindling physical supply, or if it's an unsustainable speculative rally with bears warning of a sharp correction.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as its dedicated community, often referring to themselves as the 'infected army,' is vigorously promoting its viral growth and a robust '2026 agenda' for expansion. Messages emphasize PMV's 'pure meme supremacy,' portraying it as a resilient and fun-focused project poised for significant momentum within the Solana ecosystem and the broader meme coin market.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending following its acquisition of Melt Pharmaceuticals and ahead of its Investor Day, where the company is expected to detail a path to significant revenue growth. Community sentiment is highly bullish, driven by anticipated Vevye market share expansion through major insurance formulary wins and speculation about short covering fueling further price momentum. Many investors believe the stock is currently undervalued, positioning it for substantial long-term gains within the ophthalmic sector.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo Inc. is trending with highly polarized sentiment, primarily driven by concerns over potential dilution and further reverse splits, while optimists highlight its undervalued position in AI and quantum technology, anticipating a significant short squeeze. The community eagerly awaits upcoming financial disclosures and monitors reported trading restrictions on certain platforms, adding to the stock's speculative nature amidst low volume.

The SUN.io platform is TRON's first one-stop platform that supports stablecoin swap, token mining and self-governance. After the redenomination, the new SUN token, as a multifunctional governance token on the SUN platform (similar to the CRV token of Curve DAO and the EPS token of Ellipsis), will grant token holders various rights and benefits such as the voting and governance right in the community, value capture, staking rewards, etc..

Sun Token

SUN is trending as its ongoing attempts to break through significant technical resistance levels are actively debated by the community, fueling speculation about its market direction. Many within the Tron ecosystem highlight SUN's perceived strength, with discussions also circling potential exchange-related developments and strong bullish sentiment for its future performance.

Nutanix, Inc. engages in the provision of a cloud platform leveraging web-scale engineering and consumer-grade design. It operates through the following geographic segments: United States, Europe, the Middle East, Africa, Asia Pacific, and Other Americas. The firm also provides software solutions and cloud services to customers' enterprise infrastructure. The company was founded by Dheeraj Pandey, Ajeet Singh, and Mohit Aron in 2009 and is headquartered in San Jose, CA.

Nutanix Inc - Ordinary Shares - Class A

Nutanix Inc 

Nutanix is actively discussed after announcing a significant accelerated share repurchase program, sparking community debate about its valuation. Many believe the stock is oversold and poised for a rebound, highlighting its continued success in capturing market share from VMware amid industry shifts. However, some investors remain cautious, citing recent volatility and past market reactions to earnings reports.

Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, the United Kingdom.

Caledonia Mining Corporation Plc

Caledonia Mining is trending amid revised gold royalty regulations in Zimbabwe that are easing tax concerns, alongside a sustained surge in global gold prices to new all-time highs. The community is actively discussing the company's robust profitability, growing cash flow, and the highly anticipated transformative potential of its Bilboes project, expected to significantly boost future production. Many investors believe the stock's current valuation does not yet fully reflect these strong fundamentals and the broader gold market tailwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Purchases 10,215 Shares

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L bought 10,215 shares of the stock in a transaction dated Thursday, December 18th. The stock was...

Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Acquires 16,384 Shares

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L purchased 16,384 shares of the company's stock in a transaction that occurred on Friday, December...

Suvretta Capital Management, L Acquires 10,215 Shares of Benitec Biopharma (NASDAQ:BNTC) Stock

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L acquired 10,215 shares of the stock in a transaction that occurred on Thursday, December 18th. The...

Insider Buying: Benitec Biopharma (NASDAQ:BNTC) Director Acquires 19,542 Shares of Stock

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L bought 19,542 shares of the business's stock in a transaction that occurred on Monday, December 22nd...

Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of "Moderate Buy" by Brokerages

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has earned an average rating of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat.com reports. One...

Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's  What You Should Know

The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)

Benitec Biopharma (BNTC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Franklin Resources Inc. Cuts Stake in Benitec Biopharma Limited $BNTC

Franklin Resources Inc. lowered its stake in shares of Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) by 5.6% in the 2nd quarter, according to the company in its most recent disclosure with...

HC Wainwright Has Optimistic Outlook of BNTC FY2026 Earnings

Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 EPS estimates for shares of Benitec Biopharma in a research report issued to clients...

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.

BNTC
Benitec Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BNTC News

BNTCBenitec Biopharma Inc